Pharmaxon: Normalizing neurons
Based on the fact that several CNS indications are characterized at least in part by abnormal movement of neurons, Pharmaxon S.A. is developing adhesion molecule modulators to normalize or re-establish normal neuronal connections for spinal cord injury, neurodegenerative disease and glioma. The company has three compounds in preclinical development.
In the CNS, adhesion molecules are expressed during embryonic development, when they are important for the functional organization of the nervous system and migration and final localization of neurons. Normally, they are not expressed in adults, except in lesions from trauma, like spinal cord injury (SCI), neurodegenerative disease, and cancer tumors, where they can aggravate the pathology of the injury or disease. ...